Bioventus (BVS) to Release Quarterly Earnings on Tuesday

Bioventus (NYSE:BVS) will announce its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Bioventus has set its FY 2024 guidance at 0.120-0.200 EPS.Investors interested in listening to the company’s conference call can do so using this link.

Bioventus (NYSE:BVS) last announced its earnings results on Tuesday, March 12th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The business had revenue of $135.42 million for the quarter, compared to the consensus estimate of $124.84 million. Bioventus had a negative net margin of 30.49% and a positive return on equity of 2.25%. On average, analysts expect Bioventus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Bioventus Trading Up 0.3 %

Shares of BVS opened at $3.97 on Monday. The firm’s 50 day simple moving average is $4.88 and its 200 day simple moving average is $4.58. The company has a market capitalization of $314.29 million, a P/E ratio of -1.58 and a beta of 0.63. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.53 and a quick ratio of 1.01. Bioventus has a 1-year low of $0.86 and a 1-year high of $6.08.

Analyst Upgrades and Downgrades

Separately, Craig Hallum raised their target price on shares of Bioventus from $6.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 13th.

Insider Buying and Selling at Bioventus

In other Bioventus news, CFO Mark Leonard Singleton sold 5,541 shares of the stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $5.39, for a total transaction of $29,865.99. Following the transaction, the chief financial officer now directly owns 25,665 shares in the company, valued at $138,334.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 15,720 shares of company stock worth $80,435 over the last ninety days. Insiders own 29.10% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.